These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 11361628

  • 21. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients.
    Gartland M, AVANTI Study Group.
    Antivir Ther; 2001 Jun; 6(2):127-34. PubMed ID: 11491417
    [Abstract] [Full Text] [Related]

  • 22. To AIDS and back with Norvir, D4T, 3TC and nutritional therapies. An interview with Michael Golk.
    Golk M.
    Posit Health News; 1998 Jun; (No 16):5-7. PubMed ID: 11365018
    [Abstract] [Full Text] [Related]

  • 23. A randomized, open-label, comparative trial of BID and TID dosing of saquinavir enhanced oral formulation as part of a triple therapy for advanced AIDS patients.
    Chetchotisakd P, Anunnatsiri S, Wankun J, Mootsikapun P, Boonyaprawit P.
    J Med Assoc Thai; 2002 May; 85(5):590-6. PubMed ID: 12188390
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine.
    Coplan PM, Cook JR, Carides GW, Heyse JF, Wu AW, Hammer SM, Nguyen BY, Meibohm AR, DiNubile MJ, AIDS Clinical Trials Group 320 Study Team.
    Clin Infect Dis; 2004 Aug 01; 39(3):426-33. PubMed ID: 15307012
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Twice daily dosing study of Viracept.
    AIDS Patient Care STDS; 1998 Jun 01; 12(6):493-4. PubMed ID: 11361999
    [No Abstract] [Full Text] [Related]

  • 31. A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial.
    Fox Z, Dragsted UB, Gerstoft J, Phillips AN, Kjaer J, Mathiesen L, Youle M, Katlama C, Hill A, Bruun JN, Clumeck N, Dellamonica P, Lundgren JD, COLATE study group.
    Antivir Ther; 2006 Jun 01; 11(6):761-70. PubMed ID: 17310820
    [Abstract] [Full Text] [Related]

  • 32. Long-term virological outcome in patients infected with multi-nucleoside analogue-resistant HIV-1.
    Clevenbergh P, Kirstetter M, Liotier JY, Dupon M, Philibert P, Jacomet C, Cua E, Montagne N, Schmit JC, Dellamonica P.
    Antivir Ther; 2002 Dec 01; 7(4):305-8. PubMed ID: 12553486
    [Abstract] [Full Text] [Related]

  • 33. Preliminary data on 141W94 reported.
    AIDS Patient Care STDS; 1998 Jan 01; 12(1):65-6. PubMed ID: 11361894
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Phase III results presented on amprenavir triple combination.
    AIDS Patient Care STDS; 1998 Dec 01; 12(12):941-2. PubMed ID: 11362070
    [No Abstract] [Full Text] [Related]

  • 36. The efficacy of combined zidovudine and lamivudine compared with that of combined zidovudine, lamivudine and nelfinavir in asymptomatic and early symptomatic HIV-infected children.
    Moolasart P, Likanonsakul S.
    Southeast Asian J Trop Med Public Health; 2002 Jun 01; 33(2):280-7. PubMed ID: 12236426
    [Abstract] [Full Text] [Related]

  • 37. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
    Delfraissy JF, Flandre P, Delaugerre C, Ghosn J, Horban A, Girard PM, Norton M, Rouzioux C, Taburet AM, Cohen-Codar I, Van PN, Chauvin JP.
    AIDS; 2008 Jan 30; 22(3):385-93. PubMed ID: 18195565
    [Abstract] [Full Text] [Related]

  • 38. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug 30; 13(72):144-50. PubMed ID: 15532140
    [Abstract] [Full Text] [Related]

  • 39. 96-Week MERIT ES analysis shows efficacy of Celsentri=Selzentry.
    AIDS Patient Care STDS; 2009 Aug 30; 23(8):679. PubMed ID: 19694034
    [No Abstract] [Full Text] [Related]

  • 40. Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy.
    Mouroux M, Descamps D, Izopet J, Yvon A, Delaugerre C, Matheron S, Coutellier A, Valantin MA, Bonmarchand M, Agut H, Massip P, Costagliola D, Katlama C, Brun-Vezinet F, Calvez V.
    Antivir Ther; 2001 Sep 30; 6(3):179-83. PubMed ID: 11808752
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.